Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-01-15 DOI:10.1080/14796694.2024.2444874

Tammy A Schuler, Shital Kamble, Kaushal Desai, Emily Bland, Leonid Dubrovsky, Bruce Feinberg

{"title":"Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.","authors":"Tammy A Schuler, Shital Kamble, Kaushal Desai, Emily Bland, Leonid Dubrovsky, Bruce Feinberg","doi":"10.1080/14796694.2024.2444874","DOIUrl":null,"url":null,"abstract":"Introduction: Given treatment landscape changes, understanding the prevalence of medical conditions/comorbidities influencing real-world unresectable hepatocellular carcinoma (uHCC) treatment decisions is key for improving outcomes.Patients and methods: In a retrospective chart review, physicians abstracted data from uHCC patients initiating first-line treatment (1L) between June 2020 and April 2022. Frequencies of medical conditions/comorbidities at 1L initiation were reported.Results: Among 433 patients, 77% had Barcelona Cancer Liver Clinic (BCLC)-C and 37% had Child-Pugh B status. Overall, 51% had ≥ 1 condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination regimen (e.g. atezolizumab plus bevacizumab), including upper/lower gastrointestinal bleeding risk (38%), chronic kidney disease (15%), history of thromboembolic events (12%), and autoimmune disorders (5%).Discussion: More than half of the patients had ≥ 1 medical condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination. This study provides timely insight into how immunotherapy combinations are being used in the real-world setting among a large number of patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-7"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2444874","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Given treatment landscape changes, understanding the prevalence of medical conditions/comorbidities influencing real-world unresectable hepatocellular carcinoma (uHCC) treatment decisions is key for improving outcomes.

Patients and methods: In a retrospective chart review, physicians abstracted data from uHCC patients initiating first-line treatment (1L) between June 2020 and April 2022. Frequencies of medical conditions/comorbidities at 1L initiation were reported.

Results: Among 433 patients, 77% had Barcelona Cancer Liver Clinic (BCLC)-C and 37% had Child-Pugh B status. Overall, 51% had ≥ 1 condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination regimen (e.g. atezolizumab plus bevacizumab), including upper/lower gastrointestinal bleeding risk (38%), chronic kidney disease (15%), history of thromboembolic events (12%), and autoimmune disorders (5%).

Discussion: More than half of the patients had ≥ 1 medical condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination. This study provides timely insight into how immunotherapy combinations are being used in the real-world setting among a large number of patients.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.